Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Ross Okimoto, M.D.
Ross Okimoto, M.D.

Ross Okimoto, M.D.

  • Clinical Instructor

Contact Information

Orchid: Orchid 0000-0002-4467-8476
Open Popup

Creighton University School of Medicine 2009

  • Tufts Medical Center, Internal Medicine 2012
  • UCSF Medical Center, Medical Oncology 2014
  • American Board of Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

Dr. Ross Okimoto is a medical oncologist specializing in the care of adult patients with soft tissue and bone sarcomas. He works with a team of surgeons, radiation oncologists and pathologists to provide the best possible outcomes for his patients.

Okimoto attended Creighton University School of Medicine. He completed his internal medicine residency training at Tufts Medical Center in Boston and his medical oncology fellowship at UCSF.

  Award  
  Confired By    
  Date    
  • Damon Runyon Clinical Investigator Award Finalist
  • 2021
  • National Cancer Institute R37 MERIT Award
  • 2021
  • American Society of Clinical Investigation Young Physician-Scientist Award
  • 2019
  • NIH-NCI Career Development Award (K08)
  • 2018
  • NIH-NCI Career Development Award (K08)
  • 2018 - 2023
  • UCSF DOM Cohort Iniative Award
  • 2018
  • A.P. Giannini Postdoctoral Fellowship
  • 2015
  • A physician-scientist, Okimoto conducts research in addition to providing clinical care. The overall goal of his laboratory-based investigations is to help improve outcomes for cancer patients. His current research work focuses on understanding the molecular mechanisms that promote tumor cell metastasis.

    Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0002-4467-8476 Additional info
    • Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 2021
      -
      May 2026
      Principal Investigator
    • Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis
      Sponsor:
      Sponsor ID:
      Funding Period:
      Feb 2018
      -
      Jan 2023
      Principal Investigator
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 39
    Data provided by UCSF Profiles, powered by CTSI
    1. Thomas NJ, Luck C, Shlimon N, Ponce RK, Kosibaty Z, Okimoto RA. Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma. bioRxiv. 2023 Oct 12. View in PubMed
    2. Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, Small EJ, Feng FY, Huang FW, Okimoto RA. The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. Elife. 2022 Nov 16; 11. View in PubMed
    3. Kim JW, Luck C, Wu W, Ponce RK, Lin YK, Gupta N, Okimoto RA. Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Cell Rep. 2022 10 04; 41(1):111443. View in PubMed
    4. Bennett NK, Nakaoka HJ, Laurent D, Okimoto RA, Sei Y, Horvai AE, Bivona TG, Ten Hoeve J, Graeber TG, Nakamura K, Nakamura JL. Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function. PLoS Biol. 2022 09; 20(9):e3001753. View in PubMed
    5. Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 07 01; 132(13). View in PubMed
    6. View All Publications

     

    Site Directory
      X